Global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for serious diseases.
Bristol-Myers Squibb Company is a global biopharmaceutical leader engaged in the discovery, development, licensing, manufacturing, and marketing of innovative medicines. With a diverse portfolio spanning hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and COVID-19 diseases, the company is dedicated to addressing critical medical needs worldwide. Key products include Revlimid for multiple myeloma, Eliquis for stroke prevention and DVT/PE treatment, Opdivo for anti-cancer therapy, and Pomalyst/Imnovid for multiple myeloma patients.
Additionally, Bristol-Myers Squibb offers a range of treatments such as Orencia for rheumatoid arthritis, Sprycel for chronic myeloid leukemia, Yervoy for melanoma, and Abraxane for chemotherapy. The company's innovative pipeline includes Reblozyl for beta thalassemia-related anemia, Empliciti for multiple myeloma, Zeposia for multiple sclerosis, Breyanzi for large B-cell lymphoma, Inrebic for myelofibrosis, and Onureg for acute myeloid leukemia.
Founded in 1887 and headquartered in New York, New York, Bristol-Myers Squibb serves a broad customer base including wholesalers, distributors, pharmacies, hospitals, clinics, retailers, and government agencies. Formerly known as Bristol-Myers Company, the company's commitment to advancing healthcare through groundbreaking therapies underscores its position as a leader in the biopharmaceutical industry, continuously striving to improve patient outcomes worldwide.